Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Our Technology

Liquid Biopsy Unlocking essential genomic information from a simple blood draw to transform the care of cancer patients

InVision® platform

Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients

Learn More

Our Solutions

InVisionFirst®Lung Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

InVisionFirst®Lung

Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

Find out More
Radar™ A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Radar™

A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Discover Radar™

Our Mission

We are transforming the lives of cancer patients and their families through the power of liquid biopsy

Find out More
InvisionFirst Lung - ctDNA Liquid Biopsy Test

Partnerships - for ctDNA Liquid Biopsy Tests

Partnerships

Our Technology - Liquid Biopsy Testing

Our Technology

Contact Us at Inivata

Contact Us

Latest News and Events

Inivata to be Acquired by NeoGenomics

5 May 2021

Exercise of purchase option to acquire remaining Inivata equity interest for $390m. Inivata to become a liquid biopsy focused division ... Read More

More News

Molecular Residual Disease detection in early stage breast cancer with a personalized sequencing approach

10 Apr 2021

Rosalind Cutts, Maria Coakley, Isaac Garcia-Murillas, Lara Ulrich, Karen Howarth, Warren Emmett, Malcolm Perry, Pete Ellis, Charlene ... Read More

More Publications
AACR Annual Meeting Week 2

AACR Annual Meeting Week 2

Event expiration date display - 17 - 21 MAY 2021

Location: Online Event Read More

More Events

Changing Lives

Patients are at the heart of everything we do.

Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives. 

This is the story of the first patient Inivata tested.

Find out More

Transforming the lives of Cancer Patients and Their Families

As a dynamic and innovative company, we focus on the development of ground-breaking technology in a fast-paced and international setting.

Our team of talented and driven individuals work together to combine their energy and expertise in world-class research, product development and commercialization. Join us.

See our latest open roles

 @inivata

May 5, 2021

As part of the acquisition, Inivata will remain a separate business division alongside @NeoGenomics’ growing clinical, pharma and informatics divisions, with our CEO Clive Morris becoming President of Inivata. Read more here: https://bit.ly/3aZAfen

May 5, 2021

Our acquisition by @NeoGenomics follows a $25 million minority equity investment in #Inivata in May 2020, at which the Company was granted a fixed price option to purchase the remainder of #Inivata for $390 million. Learn more here: https://bit.ly/3aZAfen

Retweet on TwitterInivata Retweeted
May 5, 2021

Precision cancer diagnostics company @Inivata agrees to $390m acquisition by @NeoGenomics, offering exits to @IPGroupplc and @cic_vc https://globaluniversityventuring.com/inivata-inspires-390m-acquisition/